Business

Accuray Appoints Healthcare Veteran James M. Hindman to Board of Directors

SUNNYVALE, Calif., Sept. 12, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) strengthened its Board of Directors with the appointment of James (Jim)

articleAccuray IncorporatedSeptember 12, 20194/company/accuray-incorporated/news/accuray-appoints-healthcare-veteran-james-m-hindman-to-board-of-directors
Accuray Appoints Healthcare Veteran James M. Hindman to Board of Directors

About this update from Accuray Incorporated

[{"type":"text","content":"SUNNYVALE, Calif., Sept. 12, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) strengthened its Board of Directors with the appointment of James (Jim) M. Hindman, effective as of September 6, 2019, and expanding the company's Board to nine members. Mr. Hindman, an experienced healthcare executive with a 30-year tenure at Allergan, Inc., is an accomplished financial executive with expertise in maximizing shareholder value. He brings significant experience in improving corporate profitability and cash flow. Mr. Hindman will serve on the Board's Audit Committee. \n\n \nMost recently, Mr. Hindman served as executive vice president, finance and business development, and chief financial officer, at Allergan. Through his guidance, Allergan achieved its most robust financial performance in its 64-year history. Mr. Hindman's previous leadership positions at Allergan include senior vice president, treasurer, risk and investor relations, and senior vice president, finance and controller. He currently serves on the Boards of publicly-traded Sienna Biopharmaceuticals and Millendo Therapeutics.\n\"Jim's appointment to the Board supports Accuray's continued focus on achieving sustained financial growth,\" said Joshua H. Levine, President and Chief Executive Officer of Accuray. \"We have confidence we are well-positioned from a product portfolio perspective to meet the needs of the radiation therapy market. When combined with the establishment of our China joint venture, we believe these two dynamics represent a real inflection point for the company. Jim's proven track record, financial acumen and business expertise will be invaluable during this pivotal point in Accuray's business.\" \n\"I am pleased to join the Accuray Board during such an exciting time for the company,\" said Mr. Hindman. \"The recent establishment of the China joint venture improves the company's long-term business prospects in China and demonstrates its commitment to sustainable growth and expanding access to its precise radiation therapy systems. I look forward to working with Josh, the other Directors and senior executive team to achieve our long-term business objectives.\"\nAbout AccurayAccuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalized and more effecti...

More updates from Accuray Incorporated